These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 8153671

  • 1. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer.
    Henry DH.
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):12-6. PubMed ID: 8153671
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH, Brooks BJ, Case DC, Fishkin E, Jacobson R, Keller AM, Kugler J, Moore J, Silver RT, Storniolo AM, Abels RI, Gordon DS, Nelson R, Larholt K, Bryant E, Rudnick S.
    Cancer J Sci Am; 1995 Oct; 1(4):252-60. PubMed ID: 9166485
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP, Abels RI, McNeill MV, Sullivan DJ.
    Arch Intern Med; 1993 Dec 13; 153(23):2669-75. PubMed ID: 8250662
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH, Abels RI.
    Semin Oncol; 1994 Apr 13; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [Abstract] [Full Text] [Related]

  • 5. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J, Koch KM.
    Clin Nephrol; 1995 Nov 13; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [Abstract] [Full Text] [Related]

  • 6. [Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer].
    Bösze P, Mayer A, Thurzó L, Kiss A, Rák K, Stumpf J.
    Orv Hetil; 1995 Nov 19; 136(47):2567-72. PubMed ID: 8532322
    [Abstract] [Full Text] [Related]

  • 7. Who should receive recombinant human erythropoietin?
    Van Stone JC.
    Semin Nephrol; 1989 Mar 19; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [Abstract] [Full Text] [Related]

  • 8. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA.
    Semin Nephrol; 1989 Mar 19; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [Abstract] [Full Text] [Related]

  • 9. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG.
    Am J Kidney Dis; 1989 Aug 19; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [Abstract] [Full Text] [Related]

  • 10. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH.
    Hematol Oncol Clin North Am; 1994 Oct 19; 8(5):961-73. PubMed ID: 7852218
    [Abstract] [Full Text] [Related]

  • 11. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin.
    Barlogie B.
    Semin Hematol; 1993 Oct 19; 30(4 Suppl 6):25-7. PubMed ID: 8153675
    [Abstract] [Full Text] [Related]

  • 12. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD, James KM, Levy JK, Browne JK, Miller A, Lobingier RT, Egrie JC.
    J Am Vet Med Assoc; 1998 Feb 15; 212(4):521-8. PubMed ID: 9491159
    [Abstract] [Full Text] [Related]

  • 13. [Recombinant human erythropoietin in anemia associated with pediatric cancer: study of the identification of predictors of response].
    León Molinari P, Jiménez Monteagudo M, Barona Zamora P, Riol Diego M, Castro Paz L, Sierrasesúmaga Ariznavarreta L.
    An Esp Pediatr; 1998 Jul 15; 49(1):17-22. PubMed ID: 9718761
    [Abstract] [Full Text] [Related]

  • 14. Guidelines for recombinant human erythropoietin therapy.
    Eschbach JW, Adamson JW.
    Am J Kidney Dis; 1989 Aug 15; 14(2 Suppl 1):2-8. PubMed ID: 2667349
    [Abstract] [Full Text] [Related]

  • 15. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
    Malik IA, Khan ZK, Hakimali A, Sabih M, Rehman G.
    J Pak Med Assoc; 1998 May 15; 48(5):127-31. PubMed ID: 9813972
    [Abstract] [Full Text] [Related]

  • 16. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.
    Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM.
    J Pain Symptom Manage; 2004 Feb 15; 27(2):185-90. PubMed ID: 15157043
    [Abstract] [Full Text] [Related]

  • 17. Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery.
    Braga M, Gianotti L, Gentilini O, Vignali A, Di Carlo V.
    Hepatogastroenterology; 1997 Feb 15; 44(15):685-90. PubMed ID: 9222672
    [Abstract] [Full Text] [Related]

  • 18. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
    Roger SD, Baker LR, Raine AE.
    Clin Nephrol; 1993 Feb 15; 39(2):103-10. PubMed ID: 8448912
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human erythropoietin treatment of anemic cancer patients.
    Henry DH.
    Cancer Pract; 1996 Feb 15; 4(4):180-4. PubMed ID: 8900758
    [Abstract] [Full Text] [Related]

  • 20. [Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma].
    Spicka I, Haber J, Petruzelka L, Kolesková E, Sálková J, Straub J, Zounar R, Klener P.
    Cas Lek Cesk; 1996 Jul 14; 135(14):450-3. PubMed ID: 8925545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.